<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637947</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-021</org_study_id>
    <nct_id>NCT02637947</nct_id>
  </id_info>
  <brief_title>Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population</brief_title>
  <acronym>MAGNETIC-VT</acronym>
  <official_title>A Prospective, Multi-center, Post Market Randomized Controlled Trial Comparing VT Ablation Outcomes Using Remote MAGNETIC Navigation Guided Substrate Mapping and Ablation Versus Manual Approach in a Low LVEF Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stereotaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stereotaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the&#xD;
      Niobeâ„¢ ES system results in superior outcomes compared to a manual approach in subjects with&#xD;
      ischemic scar VT in a low ejection fraction population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, single-blind, prospective, multi-center post market evaluation.&#xD;
      Subjects will be screened for study eligibility and asked to complete written informed&#xD;
      consent prior to any study specific testing assessments. After completing written informed&#xD;
      consent, a total of 386 subjects will be randomized on a 1:1 basis to receive VT ablation&#xD;
      treatment using either the Niobe ES or standard manual catheter ablation treatment using&#xD;
      commercially available products. This will be the largest randomized VT study comparing&#xD;
      outcomes from RMN to manually guided catheter ablation procedures. Subjects will be&#xD;
      randomized according to a computer-generated randomization scheme. Randomization will be&#xD;
      blocked at the study site level and subjects will be blinded to group assignment. Since&#xD;
      quality of life measurements will be collected during follow-up, this study is single-blinded&#xD;
      in order to mitigate patient bias. Clinical evaluations will not be masked to the treating&#xD;
      physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>freedom from any VT in the overall cohort</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute success of procedure</measure>
    <time_frame>at end of procedure (immediate)</time_frame>
    <description>non-inducibility of clinical VT and/or other monomorphic VT using typical stimulation protocol for induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from VT in large scar subpopulation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse events</measure>
    <time_frame>48 hours post-procedure</time_frame>
    <description>death, cardiac tamponade, stroke, bleeding requiring surgical intervention, progressive heart failure related to VT/VF recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Total number of appropriate ICD defibrillator shocks</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total number of ICD applications of anti-tachycardia pacing</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total procedure time (skin to skin)</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total fluoroscopy time</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total fluoroscopy dose</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total mapping time</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total ablation time</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total mapping points prior to ablation</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total ablation energy delivery</measure>
    <time_frame>through end of acute procedure, an average of 3 hours</time_frame>
    <description>Watts X seconds / Total scar surface area</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient quality of life (SF-12)</measure>
    <time_frame>12 months</time_frame>
    <description>Medical Outcomes Study 12-item Short-Form Health Survey</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>Magnetic navigation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual navigation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>catheter ablation using magnetic navigation</intervention_name>
    <description>elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.</description>
    <arm_group_label>Magnetic navigation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>catheter ablation using manual navigation</intervention_name>
    <description>elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.</description>
    <arm_group_label>Manual navigation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subject has had an ICD previously implanted&#xD;
&#xD;
          -  subject has drug-refractory monomorphic VT&#xD;
&#xD;
          -  subject is a candidate for ischemic VT RF ablation&#xD;
&#xD;
          -  subject has had a myocardial infarction&#xD;
&#xD;
          -  subject has a LVEF less than or equal to 35%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subject has non-ischemic VT&#xD;
&#xD;
          -  subject has a history of stroke within 1 month prior to enrollment&#xD;
&#xD;
          -  subject has had an acute myocardial infarction within 30 days prior to enrollment&#xD;
&#xD;
          -  subject has unstable angina&#xD;
&#xD;
          -  subject has undergone cardiac surgery within 60 days prior to enrollment&#xD;
&#xD;
          -  subject is pregnant or nursing&#xD;
&#xD;
          -  subject has a limited life expectancy of 1 year or less (Subjects requiring LVAD/IABP&#xD;
             intraprocedural support may be enrolled as long as life expectancy is at least 1 year&#xD;
             following the ablation procedure.)&#xD;
&#xD;
          -  subject is unable or unwilling to cooperate with study procedures&#xD;
&#xD;
          -  subject has a known presence of intracardiac thrombi as determined by echocardiography&#xD;
&#xD;
          -  subject has a major contraindication to anticoagulation therapy or coagulation&#xD;
             disorder&#xD;
&#xD;
          -  subject has had a previous pericarditis or cardiac tumor&#xD;
&#xD;
          -  subject has had previous thoracic radiation therapy&#xD;
&#xD;
          -  any other reason the investigator considers the subject ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Heart Institute</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <state>West Flanders</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Praha</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu De Nancy - HÃ´pitaux De Brabois</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

